XOMA Royalty Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XOMA research report →
Range $39 – $76
Price Chart
About the company
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms.
- CEO
- Owen Hughes Jr.
- IPO
- 1986
- Employees
- 14
- HQ
- EmeryVille, CA, US
Get TickerSpark's AI analysis on XOMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $710.16M
- P/E
- 24.35
- Fwd P/E
- 51.16
- PEG
- -0.17
- P/S
- 19.60
- P/B
- 4.23
- EV/EBITDA
- 14.76
- Div Yield
- 0.00%
- Gross Margin
- 93.29%
- Op Margin
- 13.73%
- Net Margin
- 86.97%
- ROE
- 30.21%
- ROIC
- 1.94%
Latest fiscal year · YoY change
- Revenue
- $52.15M+83.1%
- Gross Profit
- $49.18M+73.9%
- Op Income
- $11.38M
- Net Income
- $31.71M+329.4%
- EPS
- $1.53+192.7%
- OCF Growth
- +120.9%
- FCF Growth
- +120.9%
- 52W High
- $45.22
- 52W Low
- $22.29
- 50D MA
- $41.95
- 200D MA
- $33.57
- Beta
- 0.86
- RSI (14)
- 34
- Avg Volume
- 329.33K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
XOMA Royalty said 2025 was a foundational year, with portfolio receipts topping $50 million, royalty revenue up sharply, positive operating cash flow, and continued portfolio expansion through acquisitions and structured deals.· March 18, 2026
- Total portfolio receipts exceeded $50 million, and royalty receipts were $34 million, up 68% year over year.
- The company added 22 assets in 2025 plus 2 platform technologies, while spending only $25 million upfront on new royalty and milestone rights.
- XOMA reported positive cash flow from operations, ended with about $83 million of unrestricted cash, and cut the Blue Owl loan principal to $112.5 million.
- Management highlighted 7 commercial programs and 14 registrational-stage programs as a growing base for recurring receipts and future milestones.
- The team remained active on buybacks, returning $16 million of capital and retiring slightly more than 5% of shares outstanding.
Full-year 2025 total GAAP income and revenue was $52.1 million versus $28.5 million in 2024. Total cash receipts were $50.5 million, including about $34 million from royalties, up 68% year over year, and about $17 million of cash milestone payments. GAAP net income was $31.7 million versus a GAAP net loss of $13.8 million in 2024. G&A expenses were $36 million versus $34.5 million in 2024; R&D expense was $1.7 million. The company ended the year with approximately $83 million of unrestricted cash and cash equivalents, and the Blue Owl loan principal was reduced to $112.5 million from $123 million. Management said royalty receipts from approved products alone could be sufficient to support breakeven operating cash flows in 2027 and beyond, and said the Blue Owl loan could be fully repaid by the end of 2030 if VABYSMO trends continue. No formal quarterly or full-year numeric revenue/EPS guidance was provided.
Owen Hughes framed 2025 as a foundational year and said XOMA is approaching the point where royalty receipts alone should cover core operating costs. His emphasis was on diversification, disciplined capital deployment, and creative deal-making, including buying companies, structuring revenue-share transactions, and adding platform technologies without putting much cash at risk. He also sounded constructive on the portfolio’s long-term catalyst base, while acknowledging that clinical setbacks can occur and that the model aims to be less binary than a traditional drug developer.
Jeff Trigilio focused on the financial improvement and balance sheet flexibility. He cited $52.1 million of full-year GAAP income and revenue, $50.5 million of total receipts, $34 million of royalty receipts, $36 million of G&A, $1.7 million of R&D, and $31.7 million of net income, then noted the company ended with about $83 million of unrestricted cash. He also pointed out that share repurchases totaled $16 million for slightly more than 648,000 shares at an average price of $24.75, while the Blue Owl loan fell to $112.5 million and remains nonrecourse and self-amortizing. He added that the company may look at optimizing the capital structure, especially the preferred stock instruments, over the next 12 months.
Analysts asked about growth in royalty receipts from approved products, and management said the outlook looks strong, led by VABYSMO, OJEMDA and MIPLYFFA, though they declined to give specific guidance. On TREMFYA litigation, Owen said XOMA and its legal advisers have strong confidence in the breach claim, but emphasized it remains litigation and the outcome could go either way; he said similar relationships have historically implied low-single-digit royalties. Questions also focused on platform technologies and capital deployment: Owen said XOMA will not become a drug development company and intends to out-license the Generation Bio technologies rather than fund R&D, while management said it prioritizes quality over transaction count and will balance buybacks with new deals depending on risk-adjusted value. For Rezolute, management said the combined opportunity may be around $1 billion, with a rough 60/40 split between congenital and tumor hyperinsulinism, and said they remain encouraged by the program’s public data.
The bull case from this call is that XOMA is increasingly self-funding: royalty receipts and other portfolio cash are moving toward covering operating costs, while the company still has about $83 million of cash and room to manage debt and preferred capital. Management also pointed to a larger and more diversified portfolio, with 7 commercial programs and 14 registrational-stage programs that could drive milestones and recurring royalties over time.
The main risks are clinical and legal. Owen highlighted recent Phase III setbacks for Rezolute and Gossamer, underscoring that portfolio assets can disappoint even if XOMA is diversified. TREMFYA litigation could be valuable, but management acknowledged the outcome is uncertain and could take time, and they also noted they do not provide specific guidance on future royalty growth.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.4%
- Shares Outstanding
- 17.68M
- Float Shares
- 11.97M
of shares held by institutions
88 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bvf Inc/Il | 7.59M | ▲ 5.00M |
| Morgan Stanley | 1.70M | ▼ 4.99K |
| Woodline Partners LP | 1.11M | ▲ 474.36K |
| Newtyn Management, LLC | 709.25K | ▲ 709.25K |
| Vanguard Group Inc | 701.66K | ▲ 33.55K |
| Blackrock, Inc. | 691.97K | ▲ 45.06K |
| Vanguard Capital Management LLC | 505.17K | ▼ 44.63K |
| Opaleye Management Inc. | 338.37K | ▲ 38.37K |
| Water Island Capital LLC | 242.00K | ▲ 242.00K |
| Alpine Associates Management Inc. | 239.32K | ▲ 239.32K |
| State Street Corp | 197.76K | ▲ 4.62K |
| Millennium Management LLC | 196.31K | ▼ 8.61K |
Held by 6 ETFs
Biggest fund positions in XOMA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 14, 26 | BVF PARTNERS L P/IL | other | 772,000 |
| Jul 14, 26 | Montano Maricel Perea | other | 65 |
| Jul 14, 26 | Montano Maricel Perea | sell | 11,316 |
| Jul 14, 26 | LIMBER JOSEPH M | other | 9,532 |
| Jul 14, 26 | LIMBER JOSEPH M | sell | 10,000 |
| Jul 14, 26 | LIMBER JOSEPH M | sell | 20,000 |
| Jul 14, 26 | LIMBER JOSEPH M | sell | 8,000 |
| Jul 14, 26 | LIMBER JOSEPH M | sell | 2,366 |
| Jul 14, 26 | LIMBER JOSEPH M | sell | 5,052 |
| Jul 14, 26 | LIMBER JOSEPH M | sell | 8,167 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XOMA coverage
Recent articles, reports, and earnings notes.
No research on XOMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XOMA report →Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy
seekingalpha.com · Nov 4
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
marketbeat.com · Aug 26
Dimensional Fund Advisors LP Boosts Stock Holdings in XOMA Royalty Corporation $XOMA
defenseworld.net · Aug 13
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
globenewswire.com · Jul 14
XOMA Royalty Announces Closing of Its Acquisition by Ligand
globenewswire.com · Jul 14
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
globenewswire.com · Jun 12
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?
prnewswire.com · Jun 12
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—TMHC, CZR, XOMA, and AVNS
globenewswire.com · Jun 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.